Literature DB >> 22469782

TET2 is essential for survival and hematopoietic stem cell homeostasis.

K Shide1, T Kameda, H Shimoda, T Yamaji, H Abe, A Kamiunten, M Sekine, T Hidaka, K Katayose, Y Kubuki, S Yamamoto, T Miike, H Iwakiri, S Hasuike, K Nagata, K Marutsuka, A Iwama, T Matsuda, A Kitanaka, K Shimoda.   

Abstract

Ten-Eleven-Translocation 2 (TET2) is an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) and thereby alters the epigenetic state of DNA; somatic loss-of-function mutations of TET2 are frequently observed in patients with diverse myeloid malignancies. To study the function of TET2 in vivo, we analyzed Ayu17-449 (TET2(trap)) mice, in which a gene trap insertion in intron 2 of TET2 reduces TET2 mRNA levels to about 20% of that found in wild-type (WT) mice. TET2(trap/trap) mice were born at Mendelian frequency but died at a high rate by postnatal day 3, indicating the essential role of TET2 for survival. Loss of TET2 results in an increase in the number of hematopoietic stem cells (HSCs)/progenitors in the fetal liver, and TET2(trap/trap) HSCs exhibit an increased self-renewal ability in vivo. In competitive transplantation assays, TET2(trap/trap) HSCs possess a competitive growth advantage over WT HSCs. These data indicate that TET2 has a critical role in survival and HSC homeostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22469782     DOI: 10.1038/leu.2012.94

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  40 in total

Review 1.  The epigenetic basis of hematopoietic stem cell aging.

Authors:  Ashley Kramer; Grant A Challen
Journal:  Semin Hematol       Date:  2016-10-24       Impact factor: 3.851

2.  TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.

Authors:  Xiaopeng Tian; Yang Xu; Jia Yin; Hong Tian; Suning Chen; Depei Wu; Aining Sun
Journal:  Int J Hematol       Date:  2014-05-24       Impact factor: 2.490

Review 3.  Epigenetic Control of Stem Cell Potential during Homeostasis, Aging, and Disease.

Authors:  Isabel Beerman; Derrick J Rossi
Journal:  Cell Stem Cell       Date:  2015-06-04       Impact factor: 24.633

Review 4.  Multistep tumorigenesis in peripheral T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto
Journal:  Int J Hematol       Date:  2015-01-28       Impact factor: 2.490

Review 5.  Dysregulation of TET2 in hematologic malignancies.

Authors:  Shigeru Chiba
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 6.  TET2 in Normal and Malignant Hematopoiesis.

Authors:  Robert L Bowman; Ross L Levine
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

7.  Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.

Authors:  N Hasegawa; M Oshima; G Sashida; H Matsui; S Koide; A Saraya; C Wang; T Muto; K Takane; A Kaneda; K Shimoda; C Nakaseko; K Yokote; A Iwama
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

8.  Overlapping Requirements for Tet2 and Tet3 in Normal Development and Hematopoietic Stem Cell Emergence.

Authors:  Cheng Li; Yahui Lan; Lianna Schwartz-Orbach; Evgenia Korol; Mamta Tahiliani; Todd Evans; Mary G Goll
Journal:  Cell Rep       Date:  2015-08-06       Impact factor: 9.423

Review 9.  DNA methylation and hydroxymethylation in hematologic differentiation and transformation.

Authors:  Myunggon Ko; Jungeun An; Anjana Rao
Journal:  Curr Opin Cell Biol       Date:  2015-11-18       Impact factor: 8.382

10.  Tissue-specific DNA demethylation is required for proper B-cell differentiation and function.

Authors:  Shari Orlanski; Verena Labi; Yitzhak Reizel; Adam Spiro; Michal Lichtenstein; Rena Levin-Klein; Sergei B Koralov; Yael Skversky; Klaus Rajewsky; Howard Cedar; Yehudit Bergman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.